What Proportion BCR-ABL Fusion Transcript?

As only six studies have been reported from India, the larger population of the country remains uncovered. According to what has been reported till date, b3a2 fusion transcript is most prevalent among adults and b2a2 is found to be more prevalent among children. Thus aim of this study was to find, that in what proportion BCR-ABL fusion transcript are present in population studied and how it is affecting prognosis of CML patients.
For this study 46 patient samples were collected, out of which result was attained for 27 samples. The transcripts detection was not achieved in remaining samples due to failure in different stages of experiment. One sample had no RNA concentration and was not used for cDNA synthesis, while cDNA synthesis was done
For the sample collection, 750 μL of Tri Reagent BD was alliqouted in eppendorf tubes and taken to hospital in -20°C mini cooler. Patient’s blood or bone marrow was taken only after taking their consent. After drawing of Blood or Bone marrow from patient, 200 μL was added to the TriReagent BD and was brought back to the molecular biology laboratory of CGD for processing of the sample. The Sample collection was not biased and patients were selected randomly irrespective of whether they were on drugs or not and also in which stage of disease they were. As all patients were under treatment, so they were asked to provide the initial clinical data of the time when they were diagnosed with the
But the striking observation in the present study was that the co-expression of the e1a2+b3a2 (7.4%) was higher than in any other populations of India as well as World. Figure 40: Comparison of prevalence of BCR-ABL fusion transcripts of present study with studies conducted worldwide
Table-14 represents the clinical data of the patients, at the time of their first diagnosis with CML.
Table 14: Clinical data of CML patients

Sample Transcript Sex age Ph Platelet (lac) Spleen
(cm) Hb
(g/dL) TLC
(lac)
CML 1 b3a2 M 22 + 1.5 15 10.1 3.79
CML 4 b3a2 M 48 + 6.47 N.P 13.4 0.585
CML 5 b3a2 M 32 + 4.9 20 9 1.98
CML 6 b3a2 M 31 + 3.5 >20 9 3.65
CML 12 b2a2 F 26 + 4.16 >10 8 1.16
CML 13 b3a2 M 24 + 2.96 8 12.7 2.66
CML 16 b3a2 F 42 + 6.7 8 9.3 1.67
CML 17 b3a2+b2a2 F 27 + 1.9 18 11.6 1.31
CML 18 b3a2+e1a2 M 35 - 4.3 18 11.2 3.85
CML 19 b2a2 /b3a2 M 30 + 6 15 7.8 1.66
CML 20 b2a2 M 28 + 5.6 8 10.5 2.705
CML 21 b3a2 F 55 + 4.5 5 11.2 0.9
CML 22 b3a2 M 64 + 4.6 10 9.8 0.433
CML24 other M 49 1.63 10 12.6 1.48
CML 25 b2a2 M 55 + 7.66 2 11.2 2.195
CML 28 b3a2 F 30 - 6.95 8 6.8